A Phase 3 interventional study of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 97 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-25.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 4th largest by enrollment, is one of 4 that started in 2010, is one of 8 in phase 3, and was the 6th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2010.
This study's enrollment of 1,083 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 91 across the 18 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 18 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 16 finished, 13 (81%) have results posted.
Among the 17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd., this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2010, is one of 7 in phase 3, and was the 6th registered.
Otsuka Holdings Co., Ltd.’s Polycystic Kidney, Autosomal Dominant studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Polycystic Kidney, Autosomal Dominant:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate whether tolvaptan modifies ADPKD progression as measured by changes from Baseline (from Study 156-04-251) in total kidney volume (TKV) and renal function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 milligrams (mg) in the morning \[AM\]/15 mg in the evening \[PM\] titrated to 60 mg \[AM\]/30 mg \[PM\], then 90 mg \[AM\]/30 mg \[PM\] based on tolerability were given orally twice daily until the last participant originating from prior studies (either 156-04-251 or 156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290) who was eligible for efficacy analysis completed the Month 24.
Drug: Tolvaptan
Tablets of 15 or 30 mg
Also known as: OPC-41061, Jinarc
Percent Change From the Baseline in Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)
Total kidney volume is a measure of disease progression in the ADPKD participants. Kidney volume was assessed in T1-weighted magnetic resonance images collected at each study site and sent to a central reviewing facility. At the central reviewing facility, radiologists used proprietary software to measure the volume of both kidneys in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). The percent change in the volume of both kidneys combined was analysed using mixed-effect model repeated measures (MMRM) analysis and reported. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.
Time frame: Study Baseline (Prior to Day 1 in Study 156-04-251) to Month 24 in this study (Study 156-08-271)
Change From the Baseline in Estimated Glomerular Filtration Rate (eGFR) as Assessed by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)
Estimated Glomerular Filtration Rate (eGFR) according to CKD-EPI is calculated using the CKD-EPI equation, expressed as a single equation, is GFR = 141 × min (serum creatinine \[Scr\]/κ, 1)α × max(Scr/κ, 1)\^-1.209 × 0.993 Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1 in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in eGFR for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). MMRM was used for the analysis. This outcome measure was analyzed only in the participants enrolled from the previous - 156-04-251, as pre-specified in the protocol.
Time frame: Study Baseline (Prior to Day 1 in Study 156-04-251) to Month 24 in this study (Study 156-08-271)
Annualized Slope of Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in Study 156-08-271
Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing annualized slope of TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.
Time frame: Study Baseline (Prior to Day 1 in Study 156-08-271) to Month 24 in this study (Study 156-08-271)
Annualized Slope of eGFR (CKD-EPI) for Study 156-04-251 Participants Enrolled in Study 156-08-271
Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (CKD-EPI) (divided by each participant's years of participation) for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). eGFR was calculated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.
Time frame: Study Baseline (Prior to Day 1 in Study 156-08-271) to Month 24 (Study 156-08-271)
Annualized TKV Slope for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271
Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of TKV for the participants who received placebo in previous study (156-04-251) to annualized slope of TKV for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 and who received placebo in the previous study, as pre-specified in the protocol.
Time frame: Tolvaptan, Delayed Treated: Baseline to Month 24 in Study 156-08-271; Placebo: Baseline to Month 36 in Study 156-04-251
Annualized Slope of Renal Function (eGFRCKD-EPI) for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271
Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (calculated using CKD-EPI formula) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of eGFR (CKD-EPI) for the participants who received placebo in previous study (156-04-251) to the annualized slope of eGFR (CKD-EPI) for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 who received placebo in previous study and received tolvaptan in this study, as pre-specified in the protocol.
Time frame: Tolvaptan, Delayed Treated: Baseline to Month 24 in Study 156-08-271; Placebo: Baseline to Month 36 in Study 156-04-251
This study was conducted at 106 sites in 13 countries from 26 May 2010 to 29 Feb 2016. Eligible participants with autosomal dominant polycystic kidney disease (ADPKD) or renal impairment who completed previous tolvaptan treatment in studies: 156-04-251 (NCT00428948), 156-04-250 (NCT00413777), 156-06-260, 156-09-284 (NCT01336972), 156-09-285 (NCT01210560), and 156-09-290 (NCT01451827) were enrolled in this open-label study.
| Milestone | Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated) | Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated) | Tolvaptan (From Other Studies: Tolvaptan, Early Treated) | Tolvaptan (From Other Studies: Placebo, Delayed Treated) |
|---|---|---|---|---|
| Started | 557 | 314 | 181 | 31 |
| Completed | 507 | 256 | 143 | 22 |
| Not completed | 50 | 58 | 38 | 9 |
| Withdrew: Lost to follow-up | 7 | 3 | 7 | 3 |
| Withdrew: Adverse event | 16 | 35 | 14 | 3 |
| Withdrew: Sponsor discontinued site | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal criteria met | 3 | 0 | 2 | 1 |
| Withdrew: Physician decision | 2 | 0 | 4 | 0 |
| Withdrew: Withdrawal by subject | 21 | 18 | 11 | 2 |
Total kidney volume is a measure of disease progression in the ADPKD participants. Kidney volume was assessed in T1-weighted magnetic resonance images collected at each study site and sent to a central reviewing facility. At the central reviewing facility, radiologists used proprietary software to measure the volume of both kidneys in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). The percent change in the volume of both kidneys combined was analysed using mixed-effect model repeated measures (MMRM) analysis and reported. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.
| percent change | Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan) | Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo) |
|---|---|---|
| Percent Change From the Baseline in Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in This Study (156-08-271) | 28.66 ± 26.14 | 30.58 ± 27.21 |
Estimated Glomerular Filtration Rate (eGFR) according to CKD-EPI is calculated using the CKD-EPI equation, expressed as a single equation, is GFR = 141 × min (serum creatinine \[Scr\]/κ, 1)α × max(Scr/κ, 1)\^-1.209 × 0.993 Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1 in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in eGFR for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). MMRM was used for the analysis. This outcome measure was analyzed only in the participants enrolled from the previous - 156-04-251, as pre-specified in the protocol.
| mL/min/1.73 square meters (m^2) | Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan) | Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo) |
|---|---|---|
| Change From the Baseline in Estimated Glomerular Filtration Rate (eGFR) as Assessed by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) for Study 156-04-251 Participants Enrolled in This Study (156-08-271) | -16.77 ± 13.16 | -19.92 ± 16.40 |
Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing annualized slope of TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.
| percent change in TKV/participant-years | Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan) | Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo) |
|---|---|---|
| Annualized Slope of Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in Study 156-08-271 | 6.164 | 4.960 |
Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (CKD-EPI) (divided by each participant's years of participation) for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). eGFR was calculated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.
| ml/min/1.73m^2/participant-years | Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan) | Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo) |
|---|---|---|
| Annualized Slope of eGFR (CKD-EPI) for Study 156-04-251 Participants Enrolled in Study 156-08-271 | -3.255 | -3.142 |
Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of TKV for the participants who received placebo in previous study (156-04-251) to annualized slope of TKV for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 and who received placebo in the previous study, as pre-specified in the protocol.
| percent change in TKV/participant-years | Tolvaptan, Delayed Treated (In Study 156-08-271) | Placebo (In Study 156-04-251) |
|---|---|---|
| Annualized TKV Slope for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271 | 4.779 | 5.627 |
Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (calculated using CKD-EPI formula) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of eGFR (CKD-EPI) for the participants who received placebo in previous study (156-04-251) to the annualized slope of eGFR (CKD-EPI) for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 who received placebo in previous study and received tolvaptan in this study, as pre-specified in the protocol.
| ml/min/1.73m^2/participant-years | Tolvaptan, Delayed Treated (In Study 156-08-271) | Placebo (In Study 156-04-251) |
|---|---|---|
| Annualized Slope of Renal Function (eGFRCKD-EPI) for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271 | -3.211 | -3.572 |
Collected over From the signing of the informed consent form until the end of the study regardless of whether the participants were on or off active study medication (Up to approximately 5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated) | 5/557 (0.9%) | 143/557 (25.7%) | 528/557 (94.8%) |
| Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated) | 0/314 (0%) | 79/314 (25.2%) | 310/314 (98.7%) |
| Tolvaptan (From Other Studies: Tolvaptan, Early Treated) | 0/181 (0%) | 34/181 (18.8%) | 175/181 (96.7%) |
| Tolvaptan (From Other Studies: Placebo, Delayed Treated) | 0/31 (0%) | 5/31 (16.1%) | 29/31 (93.5%) |
| Event | Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated) | Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated) | Tolvaptan (From Other Studies: Tolvaptan, Early Treated) | Tolvaptan (From Other Studies: Placebo, Delayed Treated) |
|---|---|---|---|---|
| Accelerated Idioventricular RhythmCardiac disorders | 0/557 | 0/314 | 0/181 | 1/31 |
| Haemorrhagic Hepatic CystHepatobiliary disorders | 1/557 | 0/314 | 0/181 | 1/31 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/557 | 1/314 | 0/181 | 1/31 |
| Alanine Aminotransferase IncreasedInvestigations | 2/557 | 3/314 | 5/181 | 1/31 |
| Aspartate Aminotransferase IncreasedInvestigations | 1/557 | 1/314 | 3/181 | 1/31 |
| Blood Lactate Dehydrogenase IncreasedInvestigations | 0/557 | 0/314 | 0/181 | 1/31 |
| Essential TremorNervous system disorders | 0/557 | 0/314 | 0/181 | 1/31 |
| Blood Creatinine IncreasedInvestigations | 6/557 | 6/314 | 1/181 | 0/31 |
| Renal Cyst InfectionInfections and infestations | 9/557 | 3/314 | 2/181 | 0/31 |
| Renal Cyst HaemorrhageRenal and urinary disorders | 6/557 | 4/314 | 2/181 | 0/31 |
| Event | Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated) | Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated) | Tolvaptan (From Other Studies: Tolvaptan, Early Treated) | Tolvaptan (From Other Studies: Placebo, Delayed Treated) |
|---|---|---|---|---|
| PolyuriaRenal and urinary disorders | 231/557 | 175/314 | 111/181 | 22/31 |
| NocturiaRenal and urinary disorders | 145/557 | 111/314 | 94/181 | 17/31 |
| ThirstGeneral disorders | 261/557 | 161/314 | 80/181 | 13/31 |
| HypertensionVascular disorders | 160/557 | 82/314 | 42/181 | 2/31 |
| Renal PainRenal and urinary disorders | 147/557 | 90/314 | 43/181 | 7/31 |
| PolydipsiaMetabolism and nutrition disorders | 62/557 | 51/314 | 38/181 | 6/31 |
| HeadacheNervous system disorders | 75/557 | 56/314 | 20/181 | 2/31 |
| FatigueGeneral disorders | 53/557 | 54/314 | 32/181 | 2/31 |
| NasopharyngitisInfections and infestations | 83/557 | 55/314 | 18/181 | 4/31 |
| Blood Creatinine IncreasedInvestigations | 96/557 | 39/314 | 20/181 | 2/31 |
The enrolled sample consisted of all participants who were enrolled in this open-label study.
| Age, Continuous(years) | Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated) | Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated) | Tolvaptan (From Other Studies: Tolvaptan, Early Treated) | Tolvaptan (From Other Studies: Placebo, Delayed Treated) | Total |
|---|---|---|---|---|---|
| Mean | 42.2 ± 6.9 | 42.5 ± 7.2 | 40.0 ± 10.1 | 35.6 ± 8.7 | 41.7 ± 7.8 |
| Sex: Female, Male(Participants) | Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated) | Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated) | Tolvaptan (From Other Studies: Tolvaptan, Early Treated) | Tolvaptan (From Other Studies: Placebo, Delayed Treated) | Total |
|---|---|---|---|---|---|
| Female | 254 | 156 | 91 | 15 | 516 |
| Male | 303 | 158 | 90 | 16 | 567 |
| Ethnicity (NIH/OMB)(Participants) | Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated) | Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated) | Tolvaptan (From Other Studies: Tolvaptan, Early Treated) | Tolvaptan (From Other Studies: Placebo, Delayed Treated) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 24 | 19 | 8 | 4 | 55 |
| Not Hispanic or Latino | 471 | 249 | 172 | 27 | 919 |
| Unknown or Not Reported | 62 | 46 | 1 | 0 | 109 |
| Race/Ethnicity, Customized(Participants) | Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated) | Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated) | Tolvaptan (From Other Studies: Tolvaptan, Early Treated) | Tolvaptan (From Other Studies: Placebo, Delayed Treated) | Total |
|---|---|---|---|---|---|
| White/Caucasian | 535 | 302 | 169 | 27 | 1033 |
| Black/African American | 9 | 2 | 2 | 3 | 16 |
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 3 | 2 | 5 | 0 | 10 |
| Other | 10 | 8 | 4 | 1 | 23 |
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from May 2010 to primary completion in Feb 2016, 69 months.
Results were first posted in Oct 2021, 5 years 7 months after primary completion. A results delay was requested in Mar 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Polycystic Kidney, Autosomal Dominant →
Otsuka Pharmaceutical Development & Commercialization, Inc. →